Diaceutics PLC Multi-year contract with top five global pharma (5613O)
June 13 2022 - 2:00AM
UK Regulatory
TIDMDXRX
RNS Number : 5613O
Diaceutics PLC
13 June 2022
13 June 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Multi-year contract win with top five global pharma company
US$2m+ contract to deliver customised data insights via the DXRX
platform
Diaceutics PLC, (AIM: DXRX), a leading diagnostic
commercialisation company which provides data, intelligence, and
analytics on the healthcare market is pleased to announce that it
has secured a multi -year deal with a top five global pharma
company to deliver customised data insights via the DXRX
platform.
The three-year enterprise deal, which is in excess of US$2m in
aggregate, is a notable upsell win for Diaceutics, which has been
working with the client since 2014, and supports the move towards
enhanced multi-year recurring revenues, a key strategy for the
Company going forward.
Under the terms of this new agreement, Diaceutics will provide c
omprehensive mapping and analysis of US physicians and labs who
perform testing for non-small cell lung cancer (NSCLC). This
holistic view of the NSCLC space in which labs are performing
biomarker specific diagnostic testing means patients can be linked
to targeted therapies in this disease area.
In addition, Diaceutics will also correlate these labs to
corresponding physician testing behaviours, providing an
understanding of testing rates, methodologies and the overall
relationship between these two key stakeholder groups.
Jordan Clark, Chief Commercial Officer of Diaceutics
commented:
"This win is testament to the value of our DXRX platform,
proving that our platform continues to gain traction within the
marketplace, elevating our profile and putting us in a prime
position to continue to win large, long-term contracts.
"As the treatment of cancer has become progressively more
biomarker-driven, and with the rapid emergence of effective matched
targeted therapies, pharma companies are making attempts to define
best practices for which tests are necessary and in what target
population. The DXRX intelligence will be a vital tool in enabling
our customer to achieve this and optimising their sales
territories."
Enquiries:
Diaceutics PLC
Nick Roberts, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
Diaceutics' data capability is one of the three key value
drivers it has integrated into its unique DXRX platform alongside
its global Lab network and product suite tailored for Precision
testing.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTUUOKRUNUNAAR
(END) Dow Jones Newswires
June 13, 2022 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024
